ABSTRACT Sulforaphane (SFN) is an isothiocyanate from broccoli that induces phase 2 detoxification enzymes. We recently reported that SFN acts as a histone deacetylase (HDAC) inhibitor in human colon cancer cells in vitro, and the present study sought to extend these findings in vivo. In mice treated with a single oral dose of 10 µmol SFN, there was significant inhibition of HDAC activity in the colonic mucosa after 6 h, and immunoblots revealed a concomitant increase in acetylated histones H3 and H4, which returned to control levels by 48 h. Longer-term treatment with SFN in the diet resulted in levels of acetylated histones and p21 WAF1 in the ileum, colon, prostate, and peripheral blood mononuclear cells that were elevated compared with controls. Consistent with these findings, SFN suppressed tumor development in Apc min mice, and there was an increase in acetylated histones in the polyps, including acetylated histones specifically associated with the promoter region of the P21 and bax genes. These results provide the first evidence for HDAC inhibition by SFN in vivo and imply that such a mechanism might contribute to the cancer chemoprotective and therapeutic effects of SFN, alone or in combination with other HDAC inhibitors currently undergoing clinical trials.
HDAC inhibitors are receiving increasing interest as chemopreventive and chemotherapeutic agents against various cancers (reviewed in (12) ). Accumulating evidence suggests that alterations in acetylated histone levels may be important in the progression of colorectal cancer. For example, reduction in global acetylation of histone H4 was observed in 80% of colon carcinomas and 39% of adenomas and was correlated with advanced tumor stage and depth-oftumor invasion, suggesting a progressive loss of histone acetylation during colon tumor development (13) . Moreover, HDAC2 was elevated after loss of APC function, and inhibition of HDAC2 by siRNA in cells expressing a mutant form of APC resulted in a decrease in cell viability and induction of apoptosis (14) . Importantly, HDAC2 protein was elevated in human primary colon carcinomas compared with matched controls (14) , suggesting that HDAC2 may be a novel target for prevention and therapy. Indeed, success has been achieved in vitro with trichostatin A, butyrate, and other inhibitors of HDAC2 and related HDACs (15) (16) (17) (18) (19) (20) .
On the basis of our initial studies in human colon and prostate cancer cells in vitro, we sought to test the hypothesis that SFN might act as an HDAC inhibitor in vivo. Here, we show for the first time that a single oral dose of SFN indeed inhibited HDAC activity and induced histone acetylation in mouse colon. Long-term dietary administration of SFN suppressed polyps significantly in the Apc min mouse, and this was accompanied by increased levels of acetylated histones, both globally as well as locally in association with the promoter region of genes that are established targets of HDAC inhibitors, such as P21 and bax (12) .
MATERIALS AND METHODS

Animals
In short-term studies, C57BL/6J +/+ mice obtained at 5 wk of age from Jackson Laboratory (Bar Harbor, ME) were housed 3 per cage and fed pelleted AIN93G diet without t-butylhydroquinone (Research Diets, New Brunswick, NJ). After one week, mice were treated by gavage with 10 μmol SFN (LKT Labs, St. Paul, MN), and 6, 24, and 48 h after administration, mice were killed by CO 2 inhalation. The colon was removed, opened longitudinally, and the mucosa was scraped into lysis buffer and frozen in liquid nitrogen. A pilot study also compared SFN with one of its metabolites, SFN-N-acetylcysteine (SFN-NAC); 3 mice in each group were treated by gavage with 10 μmol SFN (LKT Labs), 10 μmol SFN-NAC (gift of F. L. Chung and C. Conaway), or vehicle alone (DMSO), and the colonic mucosa was scraped 6 h later, as described above.
In long-term studies, male C57BL/6J +/Min (Apc min ) and C57BL/6J +/+ wild-type mice, obtained from Jackson Laboratory at 6 wks of age, were housed 3 per cage and given water and food ad libitum. AIN93G diet, without t-butylhydroquinone (Research Diets), was formulated with or without 443 mg SFN/kg diet and stored in closed containers at 4°C. At 16 wk of age, and following a 12-h fast, each mouse was killed, and blood was collected by cardiac puncture. The liver and spleen were removed and weighed, and peripheral blood mononuclear cells (PBMC) were isolated from the spleens (see below). Prostates also were removed and snap-frozen in liquid nitrogen. The GI tract was excised, divided into sections (duodenum, jejunum, ileum, and colon), and cleaned with ice-cold PBS. The sections were opened longitudinally and the number, size, and location of polyps along the GI tract were recorded by individuals blinded to genotype and treatment. Polyps and adjacent normal-looking tissue were removed and snap-frozen in liquid nitrogen for Western blot analysis. Normal tissue also was collected from wild-type mice.
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PBMC isolation
Spleens were homogenized and a single-cell suspension was made by passing the homogenate sequentially through 21-and 23-gauge needles. The cell suspension was placed on Fico/Lite-LE (Atlanta Biologicals, Lawrenceville, GA) and centrifuged for 25 min at 2000 g. The PBMC layer was removed and placed in a clean tube and centrifuged for 10 min at 900 g. The pellet was placed in 90% FBS/10% DMSO and frozen in isopropyl alcohol at -80°C overnight.
Western blot analysis
Frozen portions of tissue or mucosa were placed in lysis buffer and homogenized. Whole prostates were homogenized and centrifuged at 15,000 rpm for 5 min, and the supernatant was collected. Proteins (10-20 μg) were separated by SDS-PAGE on a 4-12% bis-Tris gel (Novex, San Diego, CA) and transferred to nitrocellulose membrane (Invitrogen, Carlsbad, CA). Equal protein loading was confirmed with Amido Black staining and β-actin. The membrane was blocked for 1 h with 2% bovine serum albumin, followed by incubation with primary antibody either overnight at 4°C or for 1 h at room temperature, and ending with secondary antibody conjugated with horseradish peroxidase (Bio-Rad, Hercules, CA) for 1 h. Primary antibodies were as follows: acetylated histone H3 (Upstate, Charlottesville, VA); acetylated histone H4 (Upstate); p21 WAF1 (Biosource, Camarillo, CA); Bax (Santa Cruz Biotechnologies, Santa Cruz, CA); and β-actin (Sigma, St. Louis, MO). Detection was by Western Lightning Chemiluminescence Reagent Plus (PE Life Sciences, Boston, MA) with image analysis on an AlphaInnotech photodocumentation system. Image quantification was determined by NIH ImageJ.
Chromatin immunoprecipitation (ChIP)
Mucosa from ileum and colon was placed in 10% formalin for 15 min and centrifuged at 3000 rpm for 5 min. The pellet was washed twice with ice-cold PBS containing protease inhibitors, resuspended in SDS-lysis buffer, and frozen at -80°C. Thawed samples were sonicated on ice, and anti-acetylated histone H3 antibody was used in the Chromatin Immunoprecipitation kit (Upstate), following the manufacturer's instructions. After DNA purification by phenol-ethanol extraction, PCR was performed with the following primers/cycling conditions: P21 CATAGATGTATGTGGCTCTGC (F) and GCTGCCTCCTTATAGCGTCGG (R), 45 cycles; 95°C/60 s, 52°C/60 s and 72°C/60 s; bax CTGCTTTAACCTCCTTAGTGC (F) and GTCACGTGACTGACCGTGGAC (R), 45 cycles; 94°C/60 s, 56°C/60 s and 72°C/60 s.
HDAC activity
HDAC activity was determined using the Fluor-de-Lys HDAC activity assay kit (Biomol, Plymouth Meeting, PA), as reported previously (11) . Homogenates (25 μg total protein) from colonic mucosa, prostates, or PBMC were incubated with Fluor-de-Lys substrate for 12 min at 37°C to initiate the HDAC reaction. Fluor-de-Lys Developer was added, and the mixture was incubated for another 10 min at room temperature. Fluorescence was measured using a Spectra Max Gemini XS fluorescent plate reader (Molecular Devices, Sunnyvale, CA), with excitation at 360 nm and emission at 460 nm.
Statistics
Differences were assessed using Student's t-test for paired comparisons, or one-way ANOVA followed by Tukey's multiple comparison (Mann-Whitney U test) test for group comparisons, and the level of significance was designated as follows: *P<0.05, **P<0.01, and ***P<0.001.
RESULTS
An initial comparison of SFN with one of its metabolites, namely SFN-NAC, showed that both compounds inhibited HDAC activity significantly in mouse colonic mucosa, 6 h after single oral gavage treatment (Fig. 1A) . The relative HDAC activity was decreased by 50% with SFN-NAC and by ~65% with SFN (P<0.001 vs. controls), although SFN and SFN-NAC did not differ significantly from each other statistically. Acetylated histones corresponded well with HDAC inhibition (Fig. 1B) , such that SFN and SFN-NAC each produced an increase in both acetylated histone H3 and acetylated histone H4 in the colon, compared with controls given vehicle alone.
In time-course studies with SFN, there was a one-to twofold increase in acetylated histone H3 expression ( Fig. 2A) in mouse colonic mucosa 6 h and 24 h after single gavage administration, which returned to control levels by 48 h (Fig. 2, top) . Under the same conditions, SFN augmented acetylated histone H4 expression threefold at 6 h and twofold at 24 h in mouse colonic mucosa, returning to control levels at 48 h (Fig. 2B) . Expression of p21, a wellestablished target of HDAC inhibitors in vitro (17, 18, (21) (22) (23) (24) (25) (26) (27) (28) , was unchanged at 6 h but increased onefold over controls during the period 24-48 h after SFN dosing (Fig. 2C ).
On the basis of these findings with SFN using a single bolus dose, subsequent experiments examined changes in histone acetylation status after long-term administration of SFN in the diet. Food intake was slightly higher in wild-type mice and lower in Apc min mice given SFN, compared with mice on the control diet; however, in both test groups, mice consumed ~6 μmol SFN/day for 10 wk, with no adverse effect on body weight, hematocrit, or spleen weight (Table  1) .
Initially, expression levels of acetylated histones and p21 were examined in the ileum, colon, PBMC, and prostates of wild-type mice (Fig. 3 ). Immunoblots revealed a consistent trend toward increased acetylated histones H3 and H4, and elevated p21 expression with SFN treatment, although, in most cases, statistical significance was not attained. In the ileum and colon, the average expression of all three proteins was increased 50%-100% in mice consuming SFN compared with animals on the control diet (Fig. 3A, B) . In PBMC, p21 was augmented onefold by SFN, whereas acetylated histones were elevated approximately fourfold (Fig. 3C ). In the prostate, acetylated histones and p21 were increased 1.5-to 2.5-fold by SFN (Fig. 3D ). On the basis of the latter findings and the HDAC inhibition in human prostate epithelial cells in vitro (M. Myzak et al., Carcinogenesis, 2005 Nov. 15, Epub ahead of print), we further examined prostate tissues and detected significant inhibition of HDAC activity by SFN in vivo (P<0.01, Fig. 3E ).
In Apc min mice, tumor multiplicity was suppressed from an average of 46.2 polyps per mouse in animals fed a control diet to 22.2 polyps per mouse in animals given SFN (P<0.01, Fig. 4A ). The average tumor yield was lowered by ~50% in all regions of the intestine, but the most substantial
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inhibition was detected in the ileum (P<0.01, Fig. 4B ). In SFN vs. control groups, the mean tumor multiplicity in each region of the GI tract was as follows: duodenum 1.7/3.0 (0.57); jejunum 2.9/6.2 (0.47); ileum 17.1/35.8 (0.48), and colon 0.6/1.2 (0.50), respectively.
In normal-looking ileum mucosa and in the adjacent polyps from the ileum (Fig. 5A) , SFN produced an increase in acetylated histone H3 expression, compared with the corresponding levels seen in mice fed the control diet. In the same tissue samples, an increase in acetylated histone H4 also was detected in some (but not all) of the mice consuming SFN. In normallooking mucosa obtained from the colon (Fig. 5B) , SFN had no apparent effect on histone H3 levels, but acetylated histone H4 was increased in some of the mice. In the colon tumors that were amenable for study, an apparent increase was detected in both acetylated histone H3 and acetylated histone H4 after SFN treatment, compared with the corresponding controls (Fig. 5B) .
In vivo ChIP assays were performed on mucosa scraped from the ileum and colon of Apc min mice (Fig. 6 ). In several of the mice on the control diet, there were low or undetectable levels of acetylated histone H3 associated with the promoter region of the P21 gene; however, in mice fed SFN, a marked increase was observed in both the ileum and the colon (Fig. 6A ). Using bax primers in the ChIP assay, an increase was detected both in the ileum and colon compared with controls, signifying that the promoter region of the bax gene was associated with elevated levels of acetylated histone H3 (Fig. 6B) . Similar results also were obtained for bax using antiacetylated histone H4 antibody in the ChIP assay (data not shown), and immunoblotting confirmed a significant increase in Bax expression in the ileum polyps obtained from mice fed SFN (P<0.05, Fig. 6C ).
DISCUSSION
SFN was first identified as a potent phase 2 enzyme inducer (6) , and this provided the impetus for many subsequent studies on the possible anticarcinogenic mechanisms [see (10) for a review]. Much interest has focused on the blocking phase of chemically induced carcinogenesis, and the various detoxification pathways that augment carcinogen excretion (7-9, 29, 30). However, SFN also can be effective postinitiation, as evidenced by work in rodent models showing suppression of carcinogen-induced skin tumors and colonic aberrant crypts (8) . In vitro, SFN induces cell cycle arrest and apoptosis in cancer cells, with molecular changes that resemble the effects seen with HDAC inhibitors (12) . This prompted us to test the hypothesis that SFN might inhibit HDAC activity and thereby derepress genes that affect cell cycle checkpoint controls and apoptosis, such as P21 and bax (12) . SFN-mediated inhibition of HDAC activity was confirmed initially in human colorectal cancer cells (11) at concentrations (3-15 μM SFN) below those reported in several other mechanism studies in vitro, which used levels of 20-100 μM SFN. Subsequent work in benign prostate hyperplasia and prostate cancer cells provided further support for the hypothesis, with evidence for 1) inhibition of HDAC activity in cell lysates, 2) increased histone H3 and H4 acetylation, globally, as well as locally in association with P21 and bax promoters, We sought to extend the in vitro findings and test for HDAC inhibition in vivo, since little is known about the concentrations achieved in colonocytes for SFN or its metabolites. The latter point is important, because biochemical and molecular modeling studies suggest that, rather than the parent compound, the "ultimate" HDAC inhibitor might be SFN-cysteine (SFN-Cys), a metabolite of SFN generated via the mercapturic acid pathway. The working hypothesis is that SFN-Cys is the active HDAC inhibitor and may be formed in two ways: directly from the SFN-GSH intermediate and indirectly from SFN-NAC, when HDAC deacetylates the NAC group and regenerates SFN-Cys (11), a mechanism that could be applicable to other dietary isothiocyanates (R. Dashwood et al., Carcinogenesis, 2005 Nov. 2, Epub ahead of print, PMID: 16267097).
In the present investigation, HDAC activity was inhibited significantly in the colonic mucosa of mice after a single oral dose of SFN and SFN-NAC, and there was an increase in acetylated histones as early as 6 h after treatment, which returned to control levels by 48 h. Compared with SFN parent, SFN-NAC exhibited a slightly smaller effect on HDAC inhibition in vivo (Fig. 1A) , although we previously found that SFN-NAC was a stronger inhibitor than the parent compound when added directly to nuclear extracts in vitro (11) . This may be due to lower uptake, bioavailability and/or stability of SFN-NAC following oral dosing. Nonetheless, these findings provide evidence, for the first time in vivo, of HDAC inhibition by SFN and by one of its metabolites.
With chronic administration of SFN in the diet, acetylated histones and p21 were elevated over controls in several tissues, including systemic organs such as prostate, and HDAC activity was inhibited significantly in the prostate. The latter finding suggests that further studies are warranted on the chemoprotective properties of SFN in prostate cancer models in vivo, such as the TRAMP mouse. The increase in acetylated histone levels in tissues after chronic dietary administration of SFN was not as striking as the single oral dose of SFN; this may be due to an acquired resistance during chronic administration, and future studies will need to address this issue by including earlier time points. A marked effect was seen, however, on histone acetylation in PBMC of mice; PBMC have been used as biomarkers in human clinical trials with HDAC inhibitors suberoylanilide hydroxamic acid (SAHA) and depsipeptide (31, 32), and our results suggest that SFN might similarly affect HDAC activities in PMBC from humans consuming broccoli or broccoli sprouts. In order for humans to obtain amounts of SFN similar to what the mice consumed, and taking into account species scaling factors, one would have to consume ~1.7 kg of mature broccoli or 106 g of broccoli sprouts. However, our recent studies suggest that lower doses of SFN can achieve the same effects on HDAC activities in PBMC (M. Myzak et al., unpublished data). On the basis of these findings, future studies are planned for other tissues from SFN-treated mice, including analyses of HDAC activity and protein expression.
A recent study reported that the ileum of wild-type mice had no detectable HDAC2 protein, but normal-looking ileum and ileum polyps of mice with a truncated form of Apc (Apc 1638N ) had elevated HDAC2 protein expression (14) . Moreover, intraperitoneal injection of Apc min mice with the HDAC inhibitor valproic acid diminished tumor multiplicity, and there was an increase in acetylated histone H3 in normal-looking tissue and a decrease in HDAC2 expression in polyps from treated mice (14) . Valproic acid is a somewhat unique HDAC inhibitor in that it shows specificity for Class I HDACs and targets HDAC2 for proteosomal degradation (33, 34) , resulting in both inhibition of existing HDACs and reduction in HDAC protein levels. In the case of SFN treatment, no effects were seen on HDAC1 protein levels in immunoblots (data not shown), but other HDACs remain to be studied, including class I and class II HDACs that were inhibited in nuclear and cytoplasmic extracts (11) .
In Apc min mice, protection by SFN was most striking in the ileum, and in contrast to the findings with sulindac (35) , no increase was detected in colon tumor multiplicity. Indeed, it appeared that SFN reduced polyps in all regions of the intestine, but to confirm this statistically, it will be necessary to repeat the study with larger numbers of animals. We predict that suppression will occur in the colon, because there was an increase in global histone acetylation in colon polyps from mice fed SFN, and ChIP assays showed increased histone acetylation associated with P21 and bax. Alternative animal models, such as the 1,2-dimethylhydrazine-or 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine-induced rat, might provide greater insight into suppression of colon tumor development and HDAC inhibition by SFN in vivo.
A key question concerns the conditions under which HDAC inhibition might be most important, in the context of other proposed mechanisms of SFN action, such as checkpoint 2 kinase activation, inhibition of tubulin polymerization, and Keap1-Nrf2 signaling (10). These mechanisms are not mutually exclusive, and scenarios might exist in which they converge for greater effect. For example (Fig. 7A) , electrophilic attack by SFN on Cys residues in Keap1 facilitates the trafficking of Nrf2 from the cytoplasm to the nucleus, and subsequent Nrf2/Maf interaction on the antioxidant response element (ARE) upregulates targets such as glutathione Stransferases (GST), NAD(P)H:quinone oxidoreductase-1 (NQO1), and heme oxygenase-1 (HO-1) (36) . However, in genes that lack the ARE but have HDACs associated with their promoter regions, transcriptional activation might occur via direct effects of SFN-Cys on HDAC activity (Fig. 7B) . A third scenario involves the combination of these mechanisms (Fig. 7C) ; for Nrf2 to access the ARE and to fully activate gene expression, certain HDACs must be displaced and/or inhibited to allow recruitment of Maf or other coactivators such as nuclear promyelocytic leukemia (PML) protein, which colocalized with Nrf2 in response to induction of the ARE pathway by carotenoids (37) .
On the basis of the scenarios proposed, it would be instructive to test known ARE-inducing agents that lack a spacer and functional group (10) for their (in)ability to modulate HDAC activity, bearing in mind alternative pathways such as the activation of histone acetyltransferases. Use of the Nrf2 −/− mouse clearly implicated Nrf2 as an important player in ARE-driven gene expression by oltipraz, a chemical that lacks the structural features of a typical HDAC inhibitor (38) . SFN also was much less effective as an anticarcinogen in Nrf2 −/− mice compared with wildtype mice when administered during the initiation phase (39); however, further studies are warranted in Nrf2 −/− mice to determine whether chronic dietary administration of SFN, postinitiation, results in tumor suppression and HDAC inhibition in tissues such as the colon.
In summary, the present investigation has provided the first evidence for inhibition of HDAC activity and induction of histone acetylation in mouse colon after a single oral dose of SFN and SFN-NAC. Chronic administration of SFN in the diet suppressed tumor formation in the Apc min mouse, and there was an increase in global histone acetylation in the polyps, together with localized increases in acetylated histones associated with the promoter region of P21 and bax. These findings recapitulate key molecular alterations induced by other HDAC inhibitors, including those currently in clinical trials. We conclude that HDAC inhibition contributes to the chemopreventive and chemotherapeutic mechanisms of SFN in vivo. In both the wild-type and Apc min mice, consumption of SFN in AIN93G diet throughout the 10-week study averaged 6 µmol/mouse/day; PCV, packed cell volume; SSI, spleen somatic index, calculated as spleen weight/total body weight at termination. **P<0.01; ***P<0.001. and induce accumulation of acetylated histones in mouse colonic mucosa. Mice were treated by gavage with 10 µmol SFN, 10 µmol SFN-NAC, or vehicle alone, and colonic mucosa was isolated after 6 h. A) HDAC activity was determined as described in Materials and Methods. Data are presented as means ± SE, n = 3; ***P < 0.001. B) Colonic mucosa from each mouse was immunoblotted for acetylated histone H3 and acetylated histone H4; β-actin was used as a loading control. for 10 weeks, and expression levels of p21 and acetylated histones H3 and H4 were determined by immunoblotting for A) ileum, B) colon, C) peripheral blood mononuclear cells, and D) prostate. Relative densitometry data were obtained using NIH Image J software, normalized to β-actin. E) HDAC activity in prostate was determined as described in Materials and Methods; data are presented as means ± SE (n=3); **P < 0.01, ***P < 0.001. In ChIP assays, mucosa from the ileum and colon of Apc min mice was immunoprecipitated with acetylated histone H3 antibody, followed by PCR with primers specific for the promoter region of A) P21 or B) bax. Immunoblot data are representative of findings from two or more mice. C) Immunoblotting for Bax was performed essentially, as described for p21 (Fig. 2) , on polyps obtained from Apc min mice; data are presented as means ± SE; n = 3, all bars; *P<0.05. HO-1) , and other ARE-driven targets. B) In genes that lack the ARE but have other response elements (RE) on which corepressor (CoR)/HDAC complexes bind and inhibit transcription, SFN metabolites competitively inhibit HDAC, thereby derepressing genes such as P21 and bax. C) A third scenario combines the first two mechanisms; for Nrf2 to access the ARE and to fully activate gene expression, HDACs must be displaced and/or inhibited to allow recruitment of Maf, or other coactivators. Note: the classical model is shown in A), although a recent study reported no separation of Nrf2-Keap1 complexes after electrophilic attack on Cys151 of human Keap1 (40) .
